Sarepta indicates it's safe to continue Elevidys dosing in Europe; Epsilogen buys TigaTx

Plus, news about Vickers Venture Partners: Sarepta Therapeutics says safety board clears paused Elevidys trials: An independent data monitoring committee concluded that three studies of the Duchenne ...

Related Posts

Bayer cautions pharma sales dip this year despite major...

Mar 5, 2025  0

BIO CEO on tariffs, MAHA and the future of the biotech ...

Apr 2, 2025  0

Exelixis’ cancer drug wins approval for neuroendocrine ...

Mar 26, 2025  0

Comments

Name

Email

Comment

Post Comment